1. Home
  2. IMMR vs DTIL Comparison

IMMR vs DTIL Comparison

Compare IMMR & DTIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Immersion Corporation

IMMR

Immersion Corporation

HOLD

Current Price

$6.47

Market Cap

216.7M

Sector

Technology

ML Signal

HOLD

Logo Precision BioSciences Inc.

DTIL

Precision BioSciences Inc.

HOLD

Current Price

$7.63

Market Cap

194.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IMMR
DTIL
Founded
1993
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Computer peripheral equipment
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
216.7M
194.3M
IPO Year
1999
2019

Fundamental Metrics

Financial Performance
Metric
IMMR
DTIL
Price
$6.47
$7.63
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
2
Target Price
$13.50
$45.00
AVG Volume (30 Days)
575.1K
206.6K
Earning Date
04-13-2026
05-14-2026
Dividend Yield
5.11%
N/A
EPS Growth
N/A
N/A
EPS
0.02
N/A
Revenue
$35,013,000.00
$1,070,000,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$19.27
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.25
$3.53
52 Week High
$8.15
$8.82

Technical Indicators

Market Signals
Indicator
IMMR
DTIL
Relative Strength Index (RSI) 61.12 61.45
Support Level $6.33 $4.56
Resistance Level $6.98 $8.08
Average True Range (ATR) 0.27 0.46
MACD 0.03 -0.07
Stochastic Oscillator 67.16 64.96

Price Performance

Historical Comparison
IMMR
DTIL

About IMMR Immersion Corporation

Immersion Corp is focused on the creation, design, development, and licensing of haptic technologies that allow people to use its sense of touch more fully as it involves engaging with products and experience the digital world. The company's software focuses on applications in mobile devices, wearables, consumer, and gaming devices markets. It generates revenue from royalty and license fees, and development contract and service fees. Geographically, the company generates a majority of its revenue from Japan, followed by Korea, Germany, United States of America and other countries.

About DTIL Precision BioSciences Inc.

Precision BioSciences Inc clinical stage gene editing company utilizing its proprietary ARCUS platform to concurrently develop two clinical-stage in vivo gene editing therapies. The ARCUS platform is used to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion (inserting DNA into gene to cause expression/add function), elimination (removing a genome, e.g. viral DNA), and excision (removing a large portion of a defective gene by delivering two ARCUS nucleases in a single adeno-associated virus ("AAV")).

Share on Social Networks: